Last quarter,the FDA approved several exciting new therapies to improve patient’s lives. Amgen’s Blincyto is a newly approved drug for patients with a form of acute lymphoblastic leukemia. Blincyto will help save lives! Abbvie recently reached approval for a Hepititas C therapy. Abbvie reached 97 percent cure rate in a clinical trial. BMS continues its success with Biologics with an approval for advanced melanoma with a therapy Opdivo.
Be the first to leave a comment
You must be Logged on to comment or reply to a post.